ESMO 2024 special: Results of interim analysis of SunRISe-4

UROONCO BCa chief editor Dr. Benjamin Pradere talks to Assoc. Prof. Andrea Necchi (IT) at EMSO 2024 on the results of the interim analysis of SunRISe-4 study: TAR-200 plus cetrelimab or CET alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy. Assoc. Prof. Necchi shares details of the study rationale and design, followed by an analysis of the results, and how these data could positively im...